Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector

Gene Therapy

Volumn 5, Issue 1, 1998, Pages 65-75

  Cara, A ^a   Rybak, S M ^a   Newton, D L ^b   Crowley, R ^a   Rottschafer, S E ^b   Reitz Jr , M S ^c   Gusella, G L ^b,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c INSTITUTE OF HUMAN VIROLOGY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gene therapy; HIV 1; Internal ribosome entry site; Replication; Ribonuclease

Indexed keywords

GAG PROTEIN; NEUROTOXIN; REV PROTEIN; RIBONUCLEASE; TRANSACTIVATOR PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; EXPRESSION VECTOR; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031963348     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300545     Document Type: Article

References (34)

1. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV-1 infection Science 1996: 271: 324-328.
2. Essex M, Matsuda Z, Yu X, Lee TH Gene therapy against retroviral diseases. Leukemia 1995; 9 (Suppl. 1): 71-74.
3. Yu M, Poeschla E, Wong-Staal F. Progress towards gene therapy for HIV-1 infection Gene Therapy 1994; 1: 13-26.
4. Lori F et al. Rapid protection against human immunodeficiency virus type 1 (HTV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 Tat and Gag. Gene Therapy 1994; 1: 27-31.
5. Smythe JA et al. A Rev-inducible gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection. Proc Natl Acad Sci USA 1994; 91: 3657-3661.
6. Trono D, Feinberg MB, Baltimore D HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989; 59: 113-120.
7. Rybak SM, Newton DL, Xue Y. Rnase and Rnase immunofusions for cancer therapy. Tumor Targeting 1995; 1: 141-147.
8. Sorrentino S et al. Eosinophil-derived neurotoxin and human liver ribonuclease. J Biol Chem 1992; 267: 14859-14865.
9. Clever J, Sassetti C, Parslow TG RNA secondary structure and binding sites for gag gene product in the 5′ packaging signal of human immunodeficiency virus type 1. J Virol 1995; 69: 2101-2109.
10. Kaye JF, Richardson JH, Lever AM. cis-Acting sequences involved in human immunodeficiency virus type 1 RNA packaging. J Virol 1995, 69: 6588-6592.
11. Wakefield JK, Rhim H, Morrow CD. Minimal sequence requirements of a functional human immunodeficiency virus type 1 primer binding site. J Virol 1994; 68: 1605-1614.
12. Bohan CA et al. Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expr 1992; 2: 391-407.
13. Cara A, Cereseto A, Lori F, Reitz MS Jr. HIV-1 protein expression from synthetic circles of DNA mimicking the extra-chromosomal forms of viral DNA. J Biol Chem 1996; 271-5393-5397.
14. Smith J, Azad A, Deacon N. Identification of two novel human immunodeficiency virus type I splice acceptor sites in infected T cell lines. J Gen Virol 1992; 73: 1825-1828.
15. Saxena SK et al. Comparison of RNases and toxins upon injection into Xenopus oocytes. J Biol Chem 1991; 266: 21208-21214.
16. Kozak M. The scanning model for translation, an update. J Cell Biol 1989; 108: 229-241.
17. Pauza CD, Galindo JE , Richman DD. Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodeficiency virus type 1 infection of CEM cells. J Exp Med 1990; 172: 1035-1042.
18. Robinson HL, Zinkus DM. Accumulation of human immunodeficiency virus type 1 DNA in T cells: result of multiple infection events. J Virol 1990, 64: 4836-4841.
19. + cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected population. Proc Natl Acad Sci USA 1992; 89: 182-186.
20. Harrison GS et al. Activation of a diphtheria toxin A gene by expression of human immunodeficiency virus-1 Tat and Rev proteins in transfected cells Hum Gen Ther 1990; 2. 53-60.
21. Liu J, Woffendin C, Yang Z-Y, Nabel GJ. Regulated expression of a dominant negative form of Rev improves resistance to HIV-1 replication in T cells Gene Therapy 1994; 1: 32-37.
22. Benko DM et al. Binding of trans-dominant Rev protein of human immunodeficiency virus type 1 to the cis-acting Rev-responsive element does not affect the fate of viral mRNA. New Biol 1990; 2: 1111-1122.
23. Schwartz S, Felber BK, Pavlakis GN. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 1992; 66: 150-159
24. Carroll L et al. A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines. J Virol 1994; 68: 6047-6051.
25. Parolin C et al. Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J Virol 1994; 68: 3888-3895.
26. + cells by a recombinant human immunodeficiency virus retroviral vector. J Clin Invest 1991; 88: 1043-1047.
27. Woffendin C et al. Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci USA 1996; 93: 2889-2894.
28. Naldini L et al In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
29. Cara A et al. Self limiting, cell type-dependent replication of an integrase defective human immunodeficiency virus type 1 in primary macrophages but not lymphocytes. Virology 1995; 208: 242-248.
30. Newton DL, Nicholls PJ, Rybak SM, Youle RJ Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin anti-transferrin receptors sFv. J Biol Chem 1994; 269: 26739-26745.
31. Ghattas IR, Sanes JR, Majors JE. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol 1991; 11: 5848-5859.
32. Cara A, Pecorara M, Cornaglia-Ferraris P. Analysis of CD4 gene expression in human fetal brain and neuroblast. Cell Mol Neurobiol 1992; 12: 131-142.
33. Maciejewski PJ et al. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Med 1995; 1: 667-673.
34. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, 1989.